Quick Takeaways
- Jeffrey B. Kindler has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,568,925.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Jeffrey B. Kindler
- Location
- Allegan, MI
- Summary
- The estimated net worth of Jeffrey B. Kindler is at least $1,568,925 dollars as of 16 Mar 2026. Jeffrey B. Kindler is the Director of PRECIGEN, INC. and owns shares of PRECIGEN, INC. (PGEN) stock worth about $958K. Jeffrey B. Kindler is the Director of Praxis Precision Medicines, Inc. and owns shares of Praxis Precision Medicines, Inc. (PRAX) stock worth about $336.3K. Jeffrey B. Kindler is the Director of PERRIGO Co plc and owns shares of PERRIGO Co plc (PRGO) stock worth about $274.6K.
- Signature
- /s/ Jeffrey B. Kindler, by Donald P. Lehr, as attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Jeffrey B. Kindler and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: PRECIGEN, INC. ($957,954).
- Past-year value change for that position: -$1,460,091.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Jeffrey B. Kindler
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| PGEN | PRECIGEN, INC. | Director | $957,954 | -$1,460,091 | -60% | 13 Mar 2026 |
| PRAX | Praxis Precision Medicines, Inc. | Director | $336,332 | 06 Feb 2026 | ||
| PRGO | PERRIGO Co plc | Director | $274,639 | 14 May 2025 | ||
| PPD | PPD, Inc. | Director | 08 Dec 2021 | |||
| TERN | Terns Pharmaceuticals, Inc. | Director | 01 Feb 2026 |
Insider Transactions Reported by Jeffrey B. Kindler:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.